1633P Phase III study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): TALAPRO-2 (TP-2) China cohort

• DOI: 10.1016/j.annonc.2024.08.1714
• Publication Date: 2024-09-17T20:46:49Z
• Authors: H. Zeng; D. Ye; H. Guo; Y. Yang; B. Xue; X. Zhang; W. Xiao; J. Jiang; T. Sun; W. Chen; Y. Wang; B. Wan; D. He; Q. Zhang; H. Luo; X. Wang; J. Guo; H. Ye; H. Zhao; Y. Zhang
• Keywords: Enzalutamide